Abstract:AbstractBackgroundTriple‐negative breast cancer (TNBC) is distinguished by a significant likelihood of distant recurrence and an unfavourable prognosis. However, the underlying molecules and mechanisms have not been fully elucidated.MethodsWe investigated the expression profile and clinical relevance of chaperonin‐containing TCP1 subunit 6A (CCT6A) in TNBC. We performed cell function assays on TNBC cells with CCT6A knockdown or overexpression. To further explore the mechanism of action of CCT6A, RNA sequencing and co‐immunoprecipitation–mass spectrometry analyses were utilized. Rescue and ubiquitination assays evaluated the impact of TRIM21‐mediated CCT6A ubiquitination and degradation on TNBC progression in vitro and in vivo. Finally, we studied the potential of Ipatasertib, a pharmacological AKT inhibitor, and/or anti‐PD1 therapy in inhibiting TNBC progression.ResultsElevated CCT6A expression in TNBC patients was associated with an adverse prognosis and lymph node metastasis. Mechanistically, CCT6A facilitated cell migration, invasion, epithelial‐mesenchymal transition and proliferation by activating the phosphatidylinositol 3‐kinase (PI3K)/AKT pathway. The TRIM21 RING domain is an E3 ligase, facilitating the K48‐linked ubiquitination‐mediated degradation of CCT6A, thereby impeding TNBC progression. Moreover, in the tumour tissues of the CCT6A‐overexpressing mice, the quantity of CD8+ T cells and the concentration of secreted interferon‐gamma were decreased, whereas in the group double‐overexpression of CCT6A and TRIM21, they were elevated; the opposite was observed in the knockdown and double‐knockdown groups. Ipatasertib demonstrated enhanced efficacy in inhibiting cell proliferation, invasion and migration in TNBC cells ectopically expressing CCT6A. When Ipatasertib and anti‐PD1 therapies were combined, both the tumour volume and mass exhibited a notable reduction, while the expression of CD45+CD8+ T cells increased, and that of CD45+CD4+CTLA4+ and CD45+CD4+PD1+ T cells decreased.ConclusionsOur findings indicate that TRIM21 inhibits TNBC progression by facilitating the K48‐linked ubiquitination‐mediated degradation of CCT6A via the PI3K/AKT signalling pathway. This highlights the potential of Ipatasertib and/or anti‐PD1 as therapeutic strategies, particularly for TNBC patients overexpressing CCT6A.Key points Chaperonin TCP1 subunit 6A (CCT6A) plays an oncogenic role in triple‐negative breast cancer (TNBC) through the AKT signaling pathway. TRIM21 facilitated K48‐linked ubiquitination‐mediated degradation of CCT6A, thereby impeding TNBC progression. Our study collectively underscores the potential of Ipatasertib in conjunction with anti‐PD1 therapy as a promising strategy to counteract CCT6A/AKT hyperactivity‐driven TNBC progression.

Type X collagen knockdown inactivate ITGB1/PI3K/AKT to suppress chronic unpredictable mild stress-stimulated triple-negative breast cancer progression

A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple‐negative breast cancer

Upregulation of collagen type X alpha 1 promotes the progress of triple‐negative breast cancer via Wnt/β‐catenin signaling

MTSS1 Suppresses Mammary Tumor-Initiating Cells by Enhancing RBCK1-mediated P65 Ubiquitination

Silencing of COL3A1 Represses Proliferation, Migration, Invasion, and Immune Escape of Triple Negative Breast Cancer Cells Via Down-Regulating PD-L1 Expression

COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk

CCT6A and Triple-Negative Breast Cancer Metastasis: Activating the AKT/MDM2/P53 Pathway

Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis

3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer

Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer

USP1-WDR48 deubiquitinase complex enhances TGF-β induced epithelial–mesenchymal transition of TNBC cells via stabilizing TAK1

NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer

Chaperonin‐containing TCP1 Subunit 6A Inhibition Via TRIM21‐mediated K48‐linked Ubiquitination Suppresses Triple‐negative Breast Cancer Progression Through the AKT Signalling Pathway

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Jujuboside B Reverse CUMS-Promoted Tumor Progression via Blocking PI3K/Akt and MAPK/ERK and Dephosphorylating CREB Signaling

The promotion of non‐small cell lung cancer progression by collagen and calcium binding EGF domain 1 is mediated through the regulation of ERK/JNK/P38 phosphorylation by reactive oxygen species

Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy

CTNND1 to mediate bone metastasis of triple-negative breast cancer via regulating CXCR4.

CTSL, a prognostic marker of breast cancer, that promotes proliferation, migration, and invasion in cells in triple-negative breast cancer

TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis